NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology

Restricted access

The molecular analysis of biomarkers in oncology is rapidly advancing, but the incorporation of new molecular tests into clinical practice will require a greater understanding of the genetic changes that drive malignancy, the assays used to measure the resulting phenotypes and genotypes, and the regulatory processes that new molecular biomarkers must face to be accepted for clinical use. To address these issues and provide an overview of current molecular testing in 6 major malignancies, including glioma, breast cancer, colon cancer, lung cancer, prostate cancer, and acute myelogenous leukemia, an NCCN Task Force was convened on the topic of evaluating the clinical utility of tumor markers in oncology. The output of this meeting, contained within this report, describes the ways biomarkers have been developed and used; defines common terminology, including prognostic, predictive, and companion diagnostic markers, and analytic validity, clinical validity, and clinical utility; and proposes the use of a combination level of evidence score to aid in the evaluation of novel biomarker tests as they arise. The current state of regulatory oversight and anticipated changes in the regulation of molecular testing are also addressed.

  • 1

    American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol2003;21:2397-2406.

    • Search Google Scholar
    • Export Citation
  • 2

    HaberDAGrayNSBaselgaJ. The evolving war on cancer. Cell2011;145:19-24.

  • 3

    KhleifSNDoroshowJHHaitWN; AACR-FDA-NCI Cancer Biomarkers Collaborative. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res2010;16:3299-3318.

    • Search Google Scholar
    • Export Citation
  • 4

    MarchioCDowsettMReis-FilhoJS. Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box. BMC Med2011;9:41.

    • Search Google Scholar
    • Export Citation
  • 5

    McShaneLMAltmanDGSauerbreiW. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol2005;23:9067-9072.

  • 6

    SaijoN. Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. Cancer Treat Revin press.

  • 7

    SimonR. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med2010;7:33-47.

    • Search Google Scholar
    • Export Citation
  • 8

    FaderlSTalpazMEstrovZ. The biology of chronic myeloid leukemia. N Engl J Med1999;341:164-172.

  • 9

    GoldsteinIMarcelVOlivierM. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther2011;18:2-11.

    • Search Google Scholar
    • Export Citation
  • 10

    JoensuuHKellokumpu-LehtinenPLBonoP. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med2006;354:809-820.

    • Search Google Scholar
    • Export Citation
  • 11

    Piccart-GebhartMJProcterMLeyland-JonesB. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med2005;353:1659-1672.

    • Search Google Scholar
    • Export Citation
  • 12

    RomondEHPerezEABryantJ. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med2005;353:1673-1684.

    • Search Google Scholar
    • Export Citation
  • 13

    ChapmanPBHauschildARobertC. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med2011;364:2507-2516.

  • 14

    PollockPMMeltzerPS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell2002;2:5-7.

  • 15

    Zelboraf. Available at: http://www.gene.com/gene/products/information/zelboraf/pdf/pi.pdf. Accessed September 30 2011.

  • 16

    TeutschSMBradleyLAPalomakiGE. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med2009;11:3-14.

    • Search Google Scholar
    • Export Citation
  • 17

    BordeauxJWelshAAgarwalS. Antibody validation. Biotechniques2010;48:197-209.

  • 18

    WuYLDudognonCNguyenE. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci2006;119:2797-2806.

    • Search Google Scholar
    • Export Citation
  • 19

    MooreHMKellyABJewellSD. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol2011;119:92-101.

  • 20

    McShaneLMAltmanDGSauerbreiW. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst2005;97:1180-1184.

    • Search Google Scholar
    • Export Citation
  • 21

    SheddenKTaylorJMEnkemannSA. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med2008;14:822-827.

    • Search Google Scholar
    • Export Citation
  • 22

    XieYMinnaJD. Predicting the future for people with lung cancer. Nat Med2008;14:812-813.

  • 23

    EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual7th ed.New York: Springer-Verlag; 2009.

  • 24

    EngstromPFBloomMGDemetriGD. NCCN Molecular Testing White Paper: effectiveness, efficiency, and reimbursement. J Natl Compr Canc Netwin press.

    • Search Google Scholar
    • Export Citation
  • 25

    The Medical Device Amendments of 1976. Publ L No. 94-295 90 Stat 539 (May 28 1976).

  • 26

    FDA Rule on Analyte Specific Reagents 62 Fed Regist 62243 62249 (November 21 1997). 1997.

  • 27

    US Food and Drug Administration. Draft Guidance for Industry and Food and Drug Administration Staff. In Vitro Companion Diagnostic Devices. Available at: http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm262292.htm. Accessed October 10 2011.

    • Search Google Scholar
    • Export Citation
  • 28

    US Food and Drug Administration. Draft Guidance for Industry, Clinical Laboratories, and FDA Staff. In Vitro Diagnostic Multivariate Index Assays. Available at: www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071455.htm. Accessed October 10 2011.

    • Search Google Scholar
    • Export Citation
  • 29

    FreidlinBMcShaneLMKornEL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst2010;102:152-160.

  • 30

    SargentDJConleyBAAllegraCColletteL. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol2005;23:2020-2027.

    • Search Google Scholar
    • Export Citation
  • 31

    HayesDFBastRCDeschCE. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst1996;88:1456-1466.

    • Search Google Scholar
    • Export Citation
  • 32

    SimonRMPaikSHayesDF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst2009;101:1446-1452.

    • Search Google Scholar
    • Export Citation
  • 33

    AmadoRGWolfMPeetersM. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:1626-1634.

    • Search Google Scholar
    • Export Citation
  • 34

    KarapetisCSKhambata-FordSJonkerDJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med2008;359:1757-1765.

    • Search Google Scholar
    • Export Citation
  • 35

    BremSSBiermanPJBremH. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 2 2011. Available at: http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed October 10 2011.

    • Search Google Scholar
    • Export Citation
  • 36

    BourneTDSchiffD. Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol2010;6:695-701.

  • 37

    Hoang-XuanKCapelleLKujasM. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol2004;22:3133-3138.

    • Search Google Scholar
    • Export Citation
  • 38

    BucknerJCGesmeDJrO'FallonJR. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol2003;21:251-255.

    • Search Google Scholar
    • Export Citation
  • 39

    CairncrossGMacdonaldDLudwinS. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol1994;12:2013-2021.

    • Search Google Scholar
    • Export Citation
  • 40

    InoYBetenskyRAZlatescuMC. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res2001;7:839-845.

    • Search Google Scholar
    • Export Citation
  • 41

    KaloshiGBenouaich-AmielADiakiteF. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology2007;68:1831-1836.

    • Search Google Scholar
    • Export Citation
  • 42

    van den BentMChinotOLCairncrossJG. Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro Oncol2003;5:128-138.

    • Search Google Scholar
    • Export Citation
  • 43

    Franco-HernandezCMartinez-GlezVde CamposJM. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity. Cancer Genet Cytogenet2009;190:93-96.

    • Search Google Scholar
    • Export Citation
  • 44

    IdbaihAKouwenhovenMJeukenJ. Chromosome 1p loss evaluation in anaplastic oligodendrogliomas. Neuropathology2008;28:440-443.

  • 45

    JeukenJCornelissenSBoots-SprengerS. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn2006;8:433-443.

    • Search Google Scholar
    • Export Citation
  • 46

    SmithJSAldereteBMinnY. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene1999;18:4144-4152.

    • Search Google Scholar
    • Export Citation
  • 47

    WoehrerASanderPHaberlerC. FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice—a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS). Clin Neuropathol2011;30:47-55.

    • Search Google Scholar
    • Export Citation
  • 48

    ParsonsDWJonesSZhangX. An integrated genomic analysis of human glioblastoma multiforme. Science2008;321:1807-1812.

  • 49

    HouillierCWangXKaloshiG. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology2010;75:1560-1566.

    • Search Google Scholar
    • Export Citation
  • 50

    von DeimlingAKorshunovAHartmannC. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol2011;21:74-87.

    • Search Google Scholar
    • Export Citation
  • 51

    DubbinkHJTaalWvan MarionR. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology2009;73:1792-1795.

    • Search Google Scholar
    • Export Citation
  • 52

    CapperDWeissertSBalssJ. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol2010;20:245-254.

    • Search Google Scholar
    • Export Citation
  • 53

    CapperDZentgrafHBalssJ. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol2009;118:599-601.

  • 54

    van den BentMJDubbinkHJMarieY. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res2010;16:1597-1604.

    • Search Google Scholar
    • Export Citation
  • 55

    HartmannCHentschelBWickW. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol2010;120:707-718.

    • Search Google Scholar
    • Export Citation
  • 56

    EnglishDRYoungJPSimpsonJA. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev2008;17:1774-1780.

    • Search Google Scholar
    • Export Citation
  • 57

    LimsuiDVierkantRATillmansLS. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst2010;102:1012-1022.

    • Search Google Scholar
    • Export Citation
  • 58

    OginoSNoshoKKirknerGJ. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut2009;58:90-96.

    • Search Google Scholar
    • Export Citation
  • 59

    JonesDTKocialkowskiSLiuL. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res2008;68:8673-8677.

    • Search Google Scholar
    • Export Citation
  • 60

    AldapeKDWangMSulmanEP. RTOG 0525: molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma [abstract]. J Clin Oncol2011;29(Suppl 1):Abstract LBA2000.

    • Search Google Scholar
    • Export Citation
  • 61

    HegiMEDiserensACGorliaT. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med2005;352:997-1003.

  • 62

    StuppRHegiMEMasonWP. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol2009;10:459-466.

    • Search Google Scholar
    • Export Citation
  • 63

    StuppRMasonWPvan den BentMJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med2005;352:987-996.

  • 64

    WellerMStuppRReifenbergerG. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Nat Rev Neurol2010;6:39-51.

    • Search Google Scholar
    • Export Citation
  • 65

    NoushmehrHWeisenbergerDJDiefesK. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell2010;17:510-522.

    • Search Google Scholar
    • Export Citation
  • 66

    ToyotaMYamamotoE. DNA methylation changes in cancer. Prog Mol Biol Transl Sci2011;101:447-457.

  • 67

    HilsenbeckSGRavdinPMde MoorCA. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat1998;52:227-237.

    • Search Google Scholar
    • Export Citation
  • 68

    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365:1687-1717.

    • Search Google Scholar
    • Export Citation
  • 69

    DowsettMAllredCKnoxJ. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol2008;26:1059-1065.

    • Search Google Scholar
    • Export Citation
  • 70

    VialeGReganMMMaioranoE. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol2007;25:3846-3852.

    • Search Google Scholar
    • Export Citation
  • 71

    VialeGReganMMMaioranoE. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors—International Breast Cancer Study Group. J Clin Oncol2008;26:1404-1410.

    • Search Google Scholar
    • Export Citation
  • 72

    CarlsonRWAllredDCAndersonBO. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2 2011. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed October 18 2011.

    • Search Google Scholar
    • Export Citation
  • 73

    AllredDCCarlsonRWBerryDA. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw2009;7(Suppl 6):S1-21; quiz S22-23.

    • Search Google Scholar
    • Export Citation
  • 74

    HammondMEHayesDFDowsettM. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med2010;134:907-922.

    • Search Google Scholar
    • Export Citation
  • 75

    HammondMEHayesDFDowsettM. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol2010;28:2784-2795.

    • Search Google Scholar
    • Export Citation
  • 76

    HammondMEHayesDFWolffAC. Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol2011;29:e458.

    • Search Google Scholar
    • Export Citation
  • 77

    CarlsonRWMoenchSJHammondME. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw2006;4(Suppl 3):S1-22; quiz S23-24.

    • Search Google Scholar
    • Export Citation
  • 78

    WolffACHammondMESchwartzJN. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol2007;25:118-145.

    • Search Google Scholar
    • Export Citation
  • 79

    AlbainKSBarlowWEShakS. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol2010;11:55-65.

    • Search Google Scholar
    • Export Citation
  • 80

    PaikSShakSTangG. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med2004;351:2817-2826.

    • Search Google Scholar
    • Export Citation
  • 81

    PaikSTangGShakS. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol2006;24:3726-3734.

    • Search Google Scholar
    • Export Citation
  • 82

    HarrisLFritscheHMennelR. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol2007;25:5287-5312.

    • Search Google Scholar
    • Export Citation
  • 83

    Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med2009;11:35-41.

    • Search Google Scholar
    • Export Citation
  • 84

    Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?Genet Med2009;11:66-73.

    • Search Google Scholar
    • Export Citation
  • 85

    Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (the TAILORx trial). Available at: http://clinicaltrials.gov/ct2/show/NCT00310180. Accessed September 30 2011.

    • Search Google Scholar
    • Export Citation
  • 86

    Tamoxifen citrate letrozole anastrozole or exemestane with or without chemotherapy in treating patients with invasive Rx-PONDER breast cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01272037. Accessed September 30 2011.

    • Search Google Scholar
    • Export Citation
  • 87

    van 't VeerLJDaiHvan de VijverMJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature2002;415:530-536.

  • 88

    van de VijverMJHeYDvan 't VeerLJ. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med2002;347:1999-2009.

    • Search Google Scholar
    • Export Citation
  • 89

    CardosoFVan't VeerLRutgersE. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol2008;26:729-735.

  • 90

    CristofanilliMBuddGTEllisMJ. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med2004;351:781-791.

    • Search Google Scholar
    • Export Citation
  • 91

    HayesDFCristofanilliMBuddGT. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res2006;12:4218-4224.

    • Search Google Scholar
    • Export Citation
  • 92

    BrinkMWeijenbergMPDe GoeijAF. Fat and K-ras mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis2004;25:1619-1628.

    • Search Google Scholar
    • Export Citation
  • 93

    NoshoKIraharaNShimaK. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One2008;3:e3698.

    • Search Google Scholar
    • Export Citation
  • 94

    SamowitzWSCurtinKSchafferD. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev2000;9:1193-1197.

    • Search Google Scholar
    • Export Citation
  • 95

    BokemeyerCKohneCRougierP. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract 3506.

    • Search Google Scholar
    • Export Citation
  • 96

    Van CutsemEKohneCHHitreE. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009;360:1408-1417.

    • Search Google Scholar
    • Export Citation
  • 97

    Benson ABIIIAmolettiJPBekaii-SaabT. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 1 2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed October 18 2011.

    • Search Google Scholar
    • Export Citation
  • 98

    AllegraCJJessupJMSomerfieldMR. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol2009;27:2091-2096.

    • Search Google Scholar
    • Export Citation
  • 99

    De RoockWJonkerDJDi NicolantonioF. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA2010;304:1812-1820.

    • Search Google Scholar
    • Export Citation
  • 100

    TejparSBokemeyerCCelikI. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab [abstract]. J Clin Oncol2011;29(Suppl 1):Abstract 3511.

    • Search Google Scholar
    • Export Citation
  • 101

    de VogelSWeijenbergMPHermanJG. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. Ann Oncol2009;20:1216-1222.

    • Search Google Scholar
    • Export Citation
  • 102

    SamowitzWSAlbertsenHHerrickJ. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology2005;129:837-845.

    • Search Google Scholar
    • Export Citation
  • 103

    De RoockWClaesBBernasconiD. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol2010;11:753-762.

    • Search Google Scholar
    • Export Citation
  • 104

    Di NicolantonioFMartiniMMolinariF. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol2008;26:5705-5712.

    • Search Google Scholar
    • Export Citation
  • 105

    TolJNagtegaalIDPuntCJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med2009;361:98-99.

  • 106

    RothADTejparSDelorenziM. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 6000 trial. J Clin Oncol2010;28:466-474.

    • Search Google Scholar
    • Export Citation
  • 107

    SamowitzWSSweeneyCHerrickJ. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res2005;65:6063-6069.

    • Search Google Scholar
    • Export Citation
  • 108

    OginoSKawasakiTBrahmandamM. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn2005;7:413-421.

  • 109

    TsiatisACNorris-KirbyARichRG. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn2010;12:425-432.

    • Search Google Scholar
    • Export Citation
  • 110

    ArcilaMLauCNafaKLadanyiM. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn2011;13:64-73.

    • Search Google Scholar
    • Export Citation
  • 111

    OginoSCantorMKawasakiT. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut2006;55:1000-1006.

    • Search Google Scholar
    • Export Citation
  • 112

    WeisenbergerDJSiegmundKDCampanM. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet2006;38:787-793.

    • Search Google Scholar
    • Export Citation
  • 113

    Des GuetzGSchischmanoffONicolasP. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer2009;45:1890-1896.

    • Search Google Scholar
    • Export Citation
  • 114

    GuastadisegniCColafranceschiMOttiniLDogliottiE. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer2010;46:2788-2798.

    • Search Google Scholar
    • Export Citation
  • 115

    SargentDJMarsoniSMongesG. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol2010;28:3219-3226.

    • Search Google Scholar
    • Export Citation
  • 116

    HampelHFrankelWLMartinE. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol2008;26:5783-5788.

    • Search Google Scholar
    • Export Citation
  • 117

    HampelHFrankelWLMartinE. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med2005;352:1851-1860.

  • 118

    UmarABolandCRTerdimanJP. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst2004;96:261-268.

    • Search Google Scholar
    • Export Citation
  • 119

    UmarARisingerJIHawkETBarrettJC. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer2004;4:153-158.

  • 120

    HutchinsGSouthwardKHandleyK. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol2011;29:1261-1270.

    • Search Google Scholar
    • Export Citation
  • 121

    PopatSHubnerRHoulstonRS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol2005;23:609-618.

  • 122

    LockerGYHamiltonSHarrisJ. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol2006;24:5313-5327.

    • Search Google Scholar
    • Export Citation
  • 123

    BertagnolliMMNiedzwieckiDComptonCC. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B protocol 89803. J Clin Oncol2009;27:1814-1821.

    • Search Google Scholar
    • Export Citation
  • 124

    DomingoELaihoPOllikainenM. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet2004;41:664-668.

    • Search Google Scholar
    • Export Citation
  • 125

    JulieCTresalletCBrouquetA. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol2008;103:2825-2835; quiz 2836.

    • Search Google Scholar
    • Export Citation
  • 126

    WaneboHJRaoBPinskyCM. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med1978;299:448-451.

    • Search Google Scholar
    • Export Citation
  • 127

    WangJYTangRChiangJM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum1994;37:272-277.

  • 128

    CohenSJPuntCJIannottiN. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol2009;20:1223-1229.

    • Search Google Scholar
    • Export Citation
  • 129

    RahbariNNAignerMThorlundK. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology2010;138:1714-1726.

    • Search Google Scholar
    • Export Citation
  • 130

    TolJKoopmanMMillerMC. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol2010;21:1006-1012.

    • Search Google Scholar
    • Export Citation
  • 131

    RosenbergRMaakMSimonI. Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients [abstract]. J Clin Oncol2011;29(Suppl 1):Abstract 358.

    • Search Google Scholar
    • Export Citation
  • 132

    SalazarRRoepmanPCapellaG. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol2011;29:17-24.

    • Search Google Scholar
    • Export Citation
  • 133

    DahlinAMPalmqvistRHenrikssonML. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res2010;16:1845-1855.

    • Search Google Scholar
    • Export Citation
  • 134

    BaraultLCharon-BarraCJoosteV. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res2008;68:8541-8546.

    • Search Google Scholar
    • Export Citation
  • 135

    OginoSNoshoKKirknerGJ. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst2008;100:1734-1738.

    • Search Google Scholar
    • Export Citation
  • 136

    AhnJBChungWBMaedaO. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer2011;117:1847-1854.

  • 137

    OginoSGalonJFuchsCSDranoffG. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncolin press. doi: 10.1038/nrclinonc.2011.122.

    • Search Google Scholar
    • Export Citation
  • 138

    DahlinAMHenrikssonMLVan GuelpenB. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol2011;24:671-682.

    • Search Google Scholar
    • Export Citation
  • 139

    NoshoKBabaYTanakaN. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol2010;222:350-366.

    • Search Google Scholar
    • Export Citation
  • 140

    OginoSNoshoKIraharaN. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res2009;15:6412-6420.

    • Search Google Scholar
    • Export Citation
  • 141

    GalonJCostesASanchez-CaboF. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science2006;313:1960-1964.

    • Search Google Scholar
    • Export Citation
  • 142

    MlecnikBTosoliniMKirilovskyA. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol2011;29:610-618.

    • Search Google Scholar
    • Export Citation
  • 143

    LynchTJBellDWSordellaR. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med2004;350:2129-2139.

    • Search Google Scholar
    • Export Citation
  • 144

    PaezJGJannePALeeJC. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science2004;304:1497-1500.

  • 145

    PaoWMillerVZakowskiM. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A2004;101:13306-13311.

    • Search Google Scholar
    • Export Citation
  • 146

    RielyGJPolitiKAMillerVAPaoW. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res2006;12:7232-7241.

    • Search Google Scholar
    • Export Citation
  • 147

    ShigematsuHLinLTakahashiT. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst2005;97:339-346.

    • Search Google Scholar
    • Export Citation
  • 148

    EttingerDSAkerleyWBorghaeiH. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2 2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed October 18 2011.

    • Search Google Scholar
    • Export Citation
  • 149

    KeedyVLTeminSSomerfieldMR. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol2011;29:2121-2127.

    • Search Google Scholar
    • Export Citation
  • 150

    PaoWLadanyiM. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res2007;13:4954-4955.

    • Search Google Scholar
    • Export Citation
  • 151

    DacicS. EGFR assays in lung cancer. Adv Anat Pathol2008;15:241-247.

  • 152

    HanSWKimTYJeonYK. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res2006;12:2538-2544.

    • Search Google Scholar
    • Export Citation
  • 153

    ShollLMXiaoYJoshiV. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol2010;133:922-934.

    • Search Google Scholar
    • Export Citation
  • 154

    KosakaTYatabeYEndohH. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res2004;64:8919-8923.

    • Search Google Scholar
    • Export Citation
  • 155

    MarchettiAMilellaMFelicioniL. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia2009;11:1084-1092.

    • Search Google Scholar
    • Export Citation
  • 156

    ShigematsuHGazdarAF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer2006;118:257-262.

    • Search Google Scholar
    • Export Citation
  • 157

    MillerVARielyGJZakowskiMF. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol2008;26:1472-1478.

    • Search Google Scholar
    • Export Citation
  • 158

    PaoWMillerVAPolitiKA. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med2005;2:e73.

    • Search Google Scholar
    • Export Citation
  • 159

    PaoWWangTYRielyGJ. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med2005;2:e17.

  • 160

    KwakELBangYJCamidgeDR. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med2010;363:1693-1703.

  • 161

    RodigSJMino-KenudsonMDacicS. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res2009;15:5216-5223.

    • Search Google Scholar
    • Export Citation
  • 162

    RodigSJShapiroGI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs2010;11:1477-1490.

    • Search Google Scholar
    • Export Citation
  • 163

    An investigational drug PF-02341066 is being studied versus standard of care in patients with advanced non-small cell lung cancer with a specific gene profile involving the anaplastic lymphoma kinase (ALK) gene. Available at: http://www.clinicaltrials.gov/show/NCT00932893. Accessed September 30 2011.

    • Search Google Scholar
    • Export Citation
  • 164

    FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm. Accessed September 30 2011.

    • Search Google Scholar
    • Export Citation
  • 165

    Mino-KenudsonMChirieacLRLawK. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res2010;16:1561-1571.

    • Search Google Scholar
    • Export Citation
  • 166

    OlaussenKADunantAFouretP. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med2006;355:983-991.

    • Search Google Scholar
    • Export Citation
  • 167

    SimonGRSharmaSCantorA. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest2005;127:978-983.

    • Search Google Scholar
    • Export Citation
  • 168

    PaoWGirardN. New driver mutations in non-small-cell lung cancer. Lancet Oncol2011;12:175-180.

  • 169

    AzzoliCGBakerSJr.TeminS. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol2009;27:6251-6266.

    • Search Google Scholar
    • Export Citation
  • 170

    AndrioleGLLevinDLCrawfordED. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst2005;97:433-438.

    • Search Google Scholar
    • Export Citation
  • 171

    HugossonJCarlssonSAusG. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol2010;11:725-732.

    • Search Google Scholar
    • Export Citation
  • 172

    SchroderFHHugossonJRoobolMJ. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med2009;360:1320-1328.

  • 173

    CarterHBFerrucciLKettermannA. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst2006;98:1521-1527.

    • Search Google Scholar
    • Export Citation
  • 174

    MohlerJLArmstrongAJBahnsonRR. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4 2011. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed October 18 2011.

    • Search Google Scholar
    • Export Citation
  • 175

    FreedlandSJHumphreysEBMangoldLA. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA2005;294:433-439.

    • Search Google Scholar
    • Export Citation
  • 176

    PoundCRPartinAWEisenbergerMA. Natural history of progression after PSA elevation following radical prostatectomy. JAMA1999;281:1591-1597.

    • Search Google Scholar
    • Export Citation
  • 177

    ChunFKde la TailleAvan PoppelH. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol2009;56:659-667.

    • Search Google Scholar
    • Export Citation
  • 178

    HesselsDSchalkenJA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol2009;6:255-261.

  • 179

    RoobolMJHaeseABjartellA. Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol2011;50(Suppl 1):85-89.

  • 180

    AubinSMReidJSarnoMJ. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol2010;184:1947-1952.

    • Search Google Scholar
    • Export Citation
  • 181

    de la TailleAIraniJGraefenM. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol2011;185:2119-2125.

  • 182

    ScherHIHellerGMolinaA. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract]. J Clin Oncol2011;29(Suppl 1):Abstract LBA4517.

    • Search Google Scholar
    • Export Citation
  • 183

    BergerMFLawrenceMSDemichelisF. The genomic complexity of primary human prostate cancer. Nature2011;470:214-220.

  • 184

    MackinnonACYanBCJosephLJAl-AhmadieHA. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med2009;133:1033-1040.

    • Search Google Scholar
    • Export Citation
  • 185

    DohnerKDohnerH. Molecular characterization of acute myeloid leukemia. Haematologica2008;93:976-982.

  • 186

    MrozekKHeeremaNABloomfieldCD. Cytogenetics in acute leukemia. Blood Rev2004;18:115-136.

  • 187

    MardisERDingLDoolingDJ. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med2009;361:1058-1066.

  • 188

    MrozekKMarcucciGPaschkaP. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood2007;109:431-448.

    • Search Google Scholar
    • Export Citation
  • 189

    SwerdlowSHCampoEHarrisNL. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.

  • 190

    O'DonnellMRAbboudCNAltmanJ. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 2 2011. Available at: http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed October 18 2011.

    • Search Google Scholar
    • Export Citation
  • 191

    DohnerHEsteyEHAmadoriS. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood2010;115:453-474.

    • Search Google Scholar
    • Export Citation
  • 192

    FaliniBMecucciCTiacciE. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med2005;352:254-266.

  • 193

    SchlenkRFDohnerKKrauterJ. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med2008;358:1909-1918.

    • Search Google Scholar
    • Export Citation
  • 194

    BeckerHMarcucciGMaharryK. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol2010;28:596-604.

    • Search Google Scholar
    • Export Citation
  • 195

    KoschmiederSHalmosBLevantiniETenenDG. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol2009;27:619-628.

    • Search Google Scholar
    • Export Citation
  • 196

    BurnettAKHillsRKGreenC. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood2010;115:948-956.

    • Search Google Scholar
    • Export Citation
  • 197

    MarcucciGMaharryKRadmacherMD. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study. J Clin Oncol2008;26:5078-5087.

    • Search Google Scholar
    • Export Citation
  • 198

    TaskesenEBullingerLCorbaciogluA. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood2011;117:2469-2475.

    • Search Google Scholar
    • Export Citation
  • 199

    WoutersBJLowenbergBErpelinck-VerschuerenCA. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood2009;113:3088-3091.

    • Search Google Scholar
    • Export Citation
  • 200

    PaschkaP. Core binding factor acute myeloid leukemia. Semin Oncol2008;35:410-417.

  • 201

    PaschkaPMarcucciGRuppertAS. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol2006;24:3904-3911.

    • Search Google Scholar
    • Export Citation
  • 202

    WhitmanSPRuppertASMarcucciG. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood2007;109:5164-5167.

    • Search Google Scholar
    • Export Citation
  • 203

    TangJLHouHAChenCY. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood2009;114:5352-5361.

    • Search Google Scholar
    • Export Citation
  • 204

    GaidzikVISchlenkRFMoschnyS. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood2009;113:4505-4511.

    • Search Google Scholar
    • Export Citation
  • 205

    PaschkaPMarcucciGRuppertAS. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol2008;26:4595-4602.

    • Search Google Scholar
    • Export Citation
  • 206

    VirappanePGaleRHillsR. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol2008;26:5429-5435.

    • Search Google Scholar
    • Export Citation
  • 207

    MarcucciGMaharryKWuYZ. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol2010;28:2348-2355.

    • Search Google Scholar
    • Export Citation
  • 208

    PaschkaPSchlenkRFGaidzikVI. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol2010;28:3636-3643.

    • Search Google Scholar
    • Export Citation
  • 209

    CarbucciaNTrouplinVGelsi-BoyerV. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia2010;24:469-473.

    • Search Google Scholar
    • Export Citation
  • 210

    HaferlachCDickerFHerholzH. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia2008;22:1539-1541.

    • Search Google Scholar
    • Export Citation
  • 211

    LeyTJDingLWalterMJ. DNMT3A mutations in acute myeloid leukemia. N Engl J Med2010;363:2424-2433.

  • 212

    MetzelerKHMaharryKRadmacherMD. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol2011;29:1373-1381.

    • Search Google Scholar
    • Export Citation
  • 213

    NeubauerAMaharryKMrozekK. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol2008;26:4603-4609.

    • Search Google Scholar
    • Export Citation
  • 214

    NibourelOKosmiderOCheokM. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood2010;116:1132-1135.

    • Search Google Scholar
    • Export Citation
  • 215

    GilbertMRWangMAldapeKD. RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) [abstract]. J Clin Oncol2011;29(Suppl 1):Abstract 2006.

    • Search Google Scholar
    • Export Citation
  • 216

    JeukenJWWesselingP. MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. J Pathol2010;222:324-328.

    • Search Google Scholar
    • Export Citation
  • 217

    StraverMEGlasAMHannemannJ. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat2010;119:551-558.

    • Search Google Scholar
    • Export Citation
  • 218

    KnauerMMookSRutgersEJ. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat2010;120:655-661.

    • Search Google Scholar
    • Export Citation
  • 219

    BuddGTCristofanilliMEllisMJ. Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer. Clin Cancer Res2006;12:6403-6409.

    • Search Google Scholar
    • Export Citation
  • 220

    CristofanilliMHayesDFBuddGT. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol2005;23:1420-1430.

    • Search Google Scholar
    • Export Citation
  • 221

    De GiorgiUValeroVRohrenE. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol2009;27:3303-3311.

    • Search Google Scholar
    • Export Citation
  • 222

    TolJDijkstraJRKlompM. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer2010;46:1997-2009.

    • Search Google Scholar
    • Export Citation
  • 223

    DouillardJYShepherdFAHirshV. Molecular predictors of outcome with gefitinib and docetaxel in previously treated nonsmall-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol2010;28:744-752.

    • Search Google Scholar
    • Export Citation
  • 224

    KerrDGrayRQuirkeP. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4000.

    • Search Google Scholar
    • Export Citation
  • 225

    VenookAPNiedzwieckiDLopatinM. Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581 [abstract]. J Clin Oncol2011;29(Suppl 1):Abstract 3518.

    • Search Google Scholar
    • Export Citation
  • 226

    MokTSWuYLThongprasertS. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med2009;361:947-957.

  • 227

    YangCHFukuokaMMokTS. Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). Ann Oncol2010;21:viii1-viii2.

    • Search Google Scholar
    • Export Citation
  • 228

    FukuokaMWuYLThongprasertS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol2011;29:2866-2874.

    • Search Google Scholar
    • Export Citation
  • 229

    LeeDHParkKKimJH. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res2010;16:1307-1314.

    • Search Google Scholar
    • Export Citation
  • 230

    MaemondoMInoueAKobayashiK. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med2010;362:2380-2388.

  • 231

    MitsudomiTSteinbergSMOieHK. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res1991;51:4999-5002.

    • Search Google Scholar
    • Export Citation
  • 232

    LinardouHDahabrehIJKanaloupitiD. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and metaanalysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol2008;9:962-972.

    • Search Google Scholar
    • Export Citation
  • 233

    MaoCQiuLXLiaoRY. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer2010;69:272-278.

    • Search Google Scholar
    • Export Citation
  • 234

    FreedlandSJPartinAW. Detecting prostate cancer with molecular markers: uPM3. Rev Urol2005;7:236-238.

  • 235

    NogueiraLCorradiREasthamJA. Other biomarkers for detecting prostate cancer. BJU Int2010;105:166-169.

  • 236

    de BonoJSScherHIMontgomeryRB. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res2008;14:6302-6309.

    • Search Google Scholar
    • Export Citation
  • 237

    DanilaDCHellerGGignacGA. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res2007;13:7053-7058.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 5 5 0
Full Text Views 541 541 68
PDF Downloads 158 158 24
EPUB Downloads 0 0 0